Literature DB >> 16210477

Evaluation of serum antibody responses against the rotavirus nonstructural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection.

Esmeralda Vizzi1, Eva Calviño, Rosabel González, Irene Pérez-Schael, Max Ciarlet, Gagandeep Kang, Mary K Estes, Ferdinando Liprandi, Juan E Ludert.   

Abstract

The immune response elicited by the rotavirus nonstructural protein NSP4 and its potential role in protection against rotavirus disease are not well understood. We investigated the serological response to NSP4 and its correlation with disease protection in sera from 110 children suffering acute diarrhea, associated or not with rotavirus, and from 26 children who were recipients of the rhesus rotavirus tetravalent (RRV-TV) vaccine. We used, as antigens in an enzyme-linked immunosorbent assay (ELISA), affinity-purified recombinant NSP4 (residues 85 to 175) from strains SA11, Wa, and RRV (genotypes A, B, and C, respectively) fused to glutathione S-transferase. Seroconversion to NSP4 was observed in 54% (42/78) of the children who suffered from natural rotavirus infection and in 8% (2/26) of the RRV-TV vaccine recipients. Our findings indicate that NSP4 evokes significantly (P < 0.05) higher seroconversion rates after natural infection than after RRV-TV vaccination. The serum antibody levels to NSP4 were modest (titers of < or = 200) in most of the infected and vaccinated children. A heterotypic NSP4 response was detected in 48% of the naturally rotavirus-infected children with a detectable response to NSP4. Following natural infection or RRV-TV vaccination, NSP4 was significantly less immunogenic than the VP6 protein when these responses were independently measured by ELISA. A significant (P < 0.05) proportion of children who did not develop diarrhea associated with rotavirus had antibodies to NSP4 in acute-phase serum, suggesting that serum antibodies against NSP4 might correlate with protection from rotavirus diarrhea. In addition, previous exposures to rotavirus did not affect the NSP4 seroconversion rate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210477      PMCID: PMC1247833          DOI: 10.1128/CDLI.12.10.1157-1163.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  32 in total

1.  Sequential analysis of nonstructural protein NSP4s derived from Group A avian rotaviruses.

Authors:  Yoshio Mori; Mohammed Ali Borgan; Naoto Ito; Makoto Sugiyama; Nobuyuki Minamoto
Journal:  Virus Res       Date:  2002-10       Impact factor: 3.303

2.  Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice.

Authors:  Andrea Bertolotti-Ciarlet; Max Ciarlet; Sue E Crawford; Margaret E Conner; Mary K Estes
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

3.  Homotypic and heterotypic serum isotype-specific antibody responses to rotavirus nonstructural protein 4 and viral protein (VP) 4, VP6, and VP7 in infants who received selected live oral rotavirus vaccines.

Authors:  Lijuan Yuan; Shin-Ichi Ishida; Shinjiro Honma; John T Patton; Douglas C Hodgins; Albert Z Kapikian; Yasutaka Hoshino
Journal:  J Infect Dis       Date:  2004-04-29       Impact factor: 5.226

4.  Epidemiologic and clinical characteristics of rotavirus disease during five years of surveillance in Venezuela.

Authors:  Belén Salinas; Germán González; Rosabel González; Marisol Escalona; Mercedes Materán; Irene Pérez Schael
Journal:  Pediatr Infect Dis J       Date:  2004-10       Impact factor: 2.129

5.  Species-specific but not genotype-specific primary and secondary isotype-specific NSP4 antibody responses in gnotobiotic calves and piglets infected with homologous host bovine (NSP4[A]) or porcine (NSP4[B]) rotavirus.

Authors:  Lijuan Yuan; Shinjiro Honma; Shin-Ichi Ishida; Xiao-Yi Yan; Albert Z Kapikian; Yasutaka Hoshino
Journal:  Virology       Date:  2004-12-05       Impact factor: 3.616

6.  Species specificity and interspecies relatedness of NSP4 genetic groups by comparative NSP4 sequence analyses of animal rotaviruses.

Authors:  M Ciarlet; F Liprandi; M E Conner; M K Estes
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

Review 7.  Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model.

Authors:  Richard L Ward
Journal:  Viral Immunol       Date:  2003       Impact factor: 2.257

8.  Rotavirus nonstructural protein NSP4 induces heterotypic antibody responses during natural infection in children.

Authors:  Pratima Ray; Jyoti Malik; Ravi K Singh; Shinjini Bhatnagar; Rajiv Bahl; Ramesh Kumar; Maharaj K Bhan
Journal:  J Infect Dis       Date:  2003-05-15       Impact factor: 5.226

9.  Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children.

Authors:  T Vesikari; E Isolauri; A Delem; E D'Hondt; F E André; G Zissis
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

10.  Changes in small intestinal homeostasis, morphology, and gene expression during rotavirus infection of infant mice.

Authors:  Jos A Boshuizen; Johan H J Reimerink; Anita M Korteland-van Male; Vanessa J J van Ham; Marion P G Koopmans; Hans A Büller; Jan Dekker; Alexandra W C Einerhand
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  9 in total

1.  Higher Expression Level and Lower Toxicity of Genetically Spliced Rotavirus NSP4 in Comparison to the Full-Length Protein in E. coli.

Authors:  Mehdi Sahmani; Siavash Azari; Majid Tebianian; Nematollah Gheibi; Farzaneh Pourasgari
Journal:  Iran J Biotechnol       Date:  2016-06       Impact factor: 1.671

2.  Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4.

Authors:  Lijuan Yuan; Shinjiro Honma; Inyoung Kim; Albert Z Kapikian; Yasutaka Hoshino
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

3.  Non-structural protein NSP2 induces heterotypic antibody responses during primary rotavirus infection and reinfection in children.

Authors:  Carl D Kirkwood; Karen Boniface; Simone Richardson; Zenobia F Taraporewala; John T Patton; Ruth F Bishop
Journal:  J Med Virol       Date:  2008-06       Impact factor: 2.327

Review 4.  Rotavirus vaccines and pathogenesis: 2008.

Authors:  Joseph M Hyser; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2009-01       Impact factor: 3.287

5.  Oral Administration of a Seed-based Bivalent Rotavirus Vaccine Containing VP6 and NSP4 Induces Specific Immune Responses in Mice.

Authors:  Hao Feng; Xin Li; Weibin Song; Mei Duan; Hong Chen; Tao Wang; Jiangli Dong
Journal:  Front Plant Sci       Date:  2017-05-31       Impact factor: 5.753

6.  Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.

Authors:  Daniel Cowley; Daniel Pavlic; Nada Bogdanovic-Sakran; Karen Boniface; Carl D Kirkwood; Julie E Bines
Journal:  Hum Vaccin Immunother       Date:  2018-05-31       Impact factor: 3.452

Review 7.  Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?

Authors:  A D Steele; J C Victor; M E Carey; J E Tate; D E Atherly; C Pecenka; Z Diaz; U D Parashar; C D Kirkwood
Journal:  Hum Vaccin Immunother       Date:  2019-02-08       Impact factor: 3.452

8.  Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia.

Authors:  Daniel Cowley; Hera Nirwati; Celeste M Donato; Nada Bogdanovic-Sakran; Karen Boniface; Carl D Kirkwood; Julie E Bines
Journal:  Vaccine       Date:  2018-08-23       Impact factor: 3.641

Review 9.  Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses.

Authors:  Mark R Zweigart; Sylvia Becker-Dreps; Filemón Bucardo; Fredman González; Ralph S Baric; Lisa C Lindesmith
Journal:  Viruses       Date:  2021-10-09       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.